+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07208149

Study of MR001 Drug for Patients Aged 18-75 With Advanced Triple-Negative Breast Cancer That Has Returned or Spread After Previous Treatments

Led by Shenzhen Majory Biotechnology Co., Ltd. · Updated on 2026-02-12

42

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MR001, an investigational drug, in patients with advanced triple-negative breast cancer TNBC who have experienced disease progression after previous treatments. This Phase IbIIa open-label study aims to assess the safety, tolerability, how the body processes the drug, and its preliminary anti-tumor activity in this patient population. The study has two parts a dose escalation phase where different doses of MR001 are tested to find the maximum tolerated dose, followed by a dose expansion phase using the selected dose. MR001 is given by intravenous infusion at varying doses and schedules, including weekly and every two weeks. The dose escalation results will guide the dose used in the expansion phase. Participants will be closely monitored through laboratory tests, adverse event assessments, and imaging to measure tumor response. Key outcomes include the number of participants experiencing dose-limiting toxicities, adverse events, and pharmacokinetic measurements over approximately two years. Additional evaluations include progression-free survival, duration of response, and overall survival, with safety and drug activity tracked throughout the study period.

CONDITIONS

Brief Title

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Research Team

Q

Qingshan Xue

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here